Postbiotics against pathogens commonly involved in pediatric infectious diseases

Microorganisms

Volumn 8, Issue 10, 2020, Pages 1-22

  Mantziari, Anastasia ^a   Salminen, Seppo ^a   Szajewska, Hania ^b   Malagón Rojas, Jeadran Nevardo ^c,d  

^a UNIVERSITY OF TURKU   (Finland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

^c UNIVERSIDAD EL BOSQUE   (Colombia)

^d INSTITUTO NACIONAL DE SALUD   (Colombia)

Author keywords

Children; Common infectious diseases; Postbiotics; Probiotics; Public health

Indexed keywords

EID: 85097032462     PISSN: None     EISSN: 20762607     Source Type: Journal    
DOI: 10.3390/microorganisms8101510     Document Type: Review

References (137)

1. UN IGME Levels & Trends in Child Mortality: Report 2019, Estimates Developed by the UN Inter-Agency Group for Child Mortality Estimation; UN: New York, NY, USA, 2019.
2. WHO Maternal and Child Epidemiology Estimation Group Child Causes of Death 2000–2017; WHO: Geneva, Switzerland, 2018.
3. Troeger, C.; Blacker, B.F.; Khalil, I.A.; Rao, P.C.; Cao, S.; Zimsen, S.R.; Albertson, S.B.; Stanaway, J.D.; Deshpande, A.; Abebe, Z.; et al. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of diarrhoea in 195 countries: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Infect. Dis. 2018, 18, 1211–1228. [CrossRef]
4. Hill, C.; Guarner, F.; Reid, G.; Gibson, G.R.; Merenstein, D.J.; Pot, B.; Morelli, L.; Canani, R.B.; Flint, H.J.; Salminen, S.; et al. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat. Rev. Gastroenterol. Hepatol. 2014, 11, 506–514. [CrossRef]
5. Vuotto, C.; Longo, F.; Donelli, G. Probiotics to counteract biofilm-associated infections: Promising and conflicting data. Int. J. Oral Sci. 2014, 6, 189–194. [CrossRef]
6. Do Carmo, F.L.R.; Rabah, H.; De Oliveira Carvalho, R.D.; Gaucher, F.; Cordeiro, B.F.; da Silva, S.H.; Le Loir, Y.; Azevedo, V.; Jan, G. Extractable Bacterial Surface Proteins in Probiotic–Host Interaction. Front. Microbiol. 2018, 9. [CrossRef]
7. Kolaček, S.; Hojsak, I.; Berni Canani, R.; Guarino, A.; Indrio, F.; Orel, R.; Pot, B.; Shamir, R.; Szajewska, H.; Vandenplas, Y.; et al. Commercial Probiotic Products: A Call for Improved Quality Control. A Position Paper by the ESPGHAN Working Group for Probiotics and Prebiotics. J. Pediatr. Gastroenterol. Nutr. 2017, 65, 117–124. [CrossRef]
8. Braegger, C.; Chmielewska, A.; Decsi, T.; Kolacek, S.; Mihatsch, W.; Moreno, L.; Pieścik, M.; Puntis, J.; Shamir, R.; Szajewska, H.; et al. Supplementation of infant formula with probiotics and/or prebiotics: A systematic review and comment by the ESPGHAN committee on nutrition. J. Pediatr. Gastroenterol. Nutr. 2011, 52, 238–250. [CrossRef] [PubMed]
9. Skórka, A.; Pieścik-Lech, M.; Kołodziej, M.; Szajewska, H. To add or not to add probiotics to infant formulae? An updated systematic review. Benef. Microbes 2017, 8, 717–725. [CrossRef] [PubMed]
10. Puccetti, M.; Xiroudaki, S.; Ricci, M.; Giovagnoli, S. Postbiotic-Enabled Targeting of the Host-Microbiota-Pathogen Interface: Hints of Antibiotic Decline? Pharmaceutics 2020, 12, 624. [CrossRef] [PubMed]
11. Courvalin, P. Antibiotic resistance: The pros and cons of probiotics. Dig. Liver Dis. 2006, 38, S261–S265. [CrossRef]
12. Zheng, M.; Zhang, R.; Tian, X.; Zhou, X.; Pan, X.; Wong, A. Assessing the Risk of Probiotic Dietary Supplements in the Context of Antibiotic Resistance. Front. Microbiol. 2017, 8, 908. [CrossRef] [PubMed]
13. Embleton, N.D.; Zalewski, S.; Berrington, J.E. Probiotics for prevention of necrotizing enterocolitis and sepsis in preterm infants. Curr. Opin. Infect. Dis. 2016, 29, 256–261. [CrossRef] [PubMed]
14. Dani, C.; Coviello, C.C.; Corsini, I.I.; Arena, F.; Antonelli, A.; Rossolini, G.M. Lactobacillus Sepsis and Probiotic Therapy in Newborns: Two New Cases and Literature Review. AJP Rep. 2016, 6, e25–e29. [CrossRef] [PubMed]
15. Lahtinen, S.J. Probiotic viability – does it matter? Microb. Ecol. Health Dis. 2012, 23. [CrossRef] [PubMed]
16. Ouwehand, A.C.; Tölkkö, S.; Kulmala, J.; Salminen, S.; Salminen, E. Adhesion of inactivated probiotic strains to intestinal mucus. Lett. Appl. Microbiol. 2000, 31, 82–86. [CrossRef]
17. Corsello, G.; Carta, M.; Marinello, R.; Picca, M.; De Marco, G.; Micillo, M.; Ferrara, D.; Vigneri, P.; Cecere, G.; Ferri, P.; et al. Preventive Effect of Cow’s Milk Fermented with Lactobacillus paracasei CBA L74 on Common Infectious Diseases in Children: A Multicenter Randomized Controlled Trial. Nutrients 2017, 9, 669. [CrossRef]
18. Del Rigo-Adrover, M.M.; Knipping, K.; Garssen, J.; van Limpt, K.; Knol, J.; Franch, À.; Castell, M.; Rodríguez-lagunas, M.J.; Pérez-Cano, F.J. Prevention of Rotavirus Diarrhea in Suckling Rats by a Specific Fermented Milk Concentrate with Prebiotic Mixture. Nutrients 2019, 11, 189. [CrossRef]
19. Rudkowski, Z.; Bromirska, J. [Reduction of the duration of salmonella excretion in infants with Hylak forte]. Padiatr. Padol. 1991, 26, 111–114.
20. Nordeste, R.; Tessema, A.; Sharma, S.; Kovač, Z.; Wang, C.; Morales, R.; Griffiths, M.W. Molecules produced by probiotics prevent enteric colibacillosis in pigs. BMC Vet. Res. 2017, 13. [CrossRef]
21. Aguilar-Toalá, J.E.; Garcia-Varela, R.; Garcia, H.S.; Mata-Haro, V.; González-Córdova, A.F.; Vallejo-Cordoba, B.; Hernández-Mendoza, A. Postbiotics: An evolving term within the functional foods field. Trends Food Sci. Technol. 2018, 75, 105–114. [CrossRef]
22. Kanauchi, O.; Andoh, A.; AbuBakar, S.; Yamamoto, N. Probiotics and Paraprobiotics in Viral Infection: Clinical Application and Effects on the Innate and Acquired Immune Systems. Curr. Pharm. Des. 2018, 24, 710–717. [CrossRef]
23. Shenderov, B.A. Metabiotics: Novel idea or natural development of probiotic conception. Microb. Ecol. Health Dis. 2013, 24. [CrossRef]
24. Bajpai, V.K.; Chandra, V.; Kim, N.-H.; Rai, R.; Kumar, P.; Kim, K.; Aeron, A.; Kang, S.C.; Maheshwari, D.K.; Na, M.; et al. Ghost probiotics with a combined regimen: A novel therapeutic approach against the Zika virus, an emerging world threat. Crit. Rev. Biotechnol. 2018, 38, 438–454. [CrossRef] [PubMed]
25. Lee, E.-S.; Song, E.-J.; Nam, Y.-D.; Lee, S.-Y. Probiotics in human health and disease: From nutribiotics to pharmabiotics. J. Microbiol. 2018, 56, 773–782. [CrossRef]
26. Collado, M.C.; Vinderola, G.; Salminen, S. Postbiotics: Facts and open questions. A position paper on the need for a consensus definition. Benef. Microbes 2019, 10, 711–719. [CrossRef] [PubMed]
27. Żółkiewicz, J.; Marzec, A.; Ruszczyński, M.; Feleszko, W. Postbiotics—A Step Beyond Pre-and Probiotics. Nutrients 2020, 12, 2189. [CrossRef]
28. Taverniti, V.; Guglielmetti, S. The immunomodulatory properties of probiotic microorganisms beyond their viability (ghost probiotics: Proposal of paraprobiotic concept). Genes Nutr. 2011, 6, 261–274. [CrossRef]
29. Malagón-Rojas, J.N.; Mantziari, A.; Salminen, S.; Szajewska, H. Postbiotics for Preventing and Treating Common Infectious Diseases in Children: A Systematic Review. Nutrients 2020, 12, 389. [CrossRef]
30. Jayamani, E.; Mylonakis, E. Effector triggered manipulation of host immune response elicited by different pathotypes of Escherichia coli. Virulence 2014, 5, 733–739. [CrossRef]
31. Kim, Y.K.; Shin, J.-S.; Nahm, M.H. NOD-Like Receptors in Infection, Immunity, and Diseases. Yonsei Med. J. 2016, 57, 5–14. [CrossRef]
32. Fenini, G.; Contassot, E.; French, L.E. Potential of IL-1, IL-18 and Inflammasome Inhibition for the Treatment of Inflammatory Skin Diseases. Front. Pharmacol. 2017, 8. [CrossRef]
33. Kummer, J.A.; Broekhuizen, R.; Everett, H.; Agostini, L.; Kuijk, L.; Martinon, F.; van Bruggen, R.; Tschopp, J. Inflammasome Components NALP 1 and 3 Show Distinct but Separate Expression Profiles in Human Tissues Suggesting a Site-specific Role in the Inflammatory Response. J. Histochem. Cytochem. 2007. [CrossRef] [PubMed]
34. Warshakoon, H.J.; Hood, J.D.; Kimbrell, M.R.; Malladi, S.; Wu, W.Y.; Shukla, N.M.; Agnihotri, G.; Sil, D.; David, S.A. Potential adjuvantic properties of innate immune stimuli. Hum. Vaccin. 2009, 5, 381–394. [CrossRef] [PubMed]
35. Chandler, C.E.; Ernst, R.K. Bacterial lipids: Powerful modifiers of the innate immune response. F1000Research 2017, 6. [CrossRef] [PubMed]
36. Petes, C.; Odoardi, N.; Gee, K. The Toll for Trafficking: Toll-Like Receptor 7 Delivery to the Endosome. Front. Immunol. 2017, 8. [CrossRef]
37. Dalpke, A.; Frank, J.; Peter, M.; Heeg, K. Activation of Toll-Like Receptor 9 by DNA from Different Bacterial Species. Infect. Immun. 2006, 74, 940–946. [CrossRef]
38. Yu, S.; Gao, N. Compartmentalizing Intestinal Epithelial Cell Toll-like Receptors for Immune Surveillance. Cell. Mol. Life Sci. CMLS 2015, 72, 3343–3353. [CrossRef]
39. Wojdasiewicz, P.; Poniatowski, Ł.A.; Szukiewicz, D. The Role of Inflammatory and Anti-Inflammatory Cytokines in the Pathogenesis of Osteoarthritis. Mediators Inflamm. 2014, 2014. [CrossRef]
40. Srinivasan, L.; Harris, M.C.; Kilpatrick, L.E. 128-Cytokines and Inflammatory Response in the Fetus and Neonate. In Fetal and Neonatal Physiology, Polin, R.A., Abman, S.H., Rowitch, D.H., Benitz, W.E., Fox, W.W., Eds.; 5th ed.; Elsevier: Amsterdam, The Netherlands, 2017; pp. 1241–1254. ISBN 978-0-323-35214-7.
41. Azad, M.A.K.; Sarker, M.; Wan, D. Immunomodulatory Effects of Probiotics on Cytokine Profiles. Available online: https://www.hindawi.com/journals/bmri/2018/8063647/(accessed on 7 April 2019).
42. Miyazawa, K.; He, F.; Kawase, M.; Kubota, A.; Yoda, K.; Hiramatsu, M. Enhancement of immunoregulatory effects of Lactobacillus gasseri TMC0356 by heat treatment and culture medium. Lett. Appl. Microbiol. 2011, 53, 210–216. [CrossRef]
43. Zagato, E.; Mileti, E.; Massimiliano, L.; Fasano, F.; Budelli, A.; Penna, G.; Rescigno, M. Lactobacillus paracasei CBA L74 Metabolic Products and Fermented Milk for Infant Formula Have Anti-Inflammatory Activity on Dendritic Cells In Vitro and Protective Effects against Colitis and an Enteric Pathogen In Vivo. PLoS ONE 2014, 9. [CrossRef]
44. Wang, H.; Yan, Y.; Wang, J.; Zhang, H.; Qi, W. Production and Characterization of Antifungal Compounds Produced by Lactobacillus plantarum IMAU10014. PLoS ONE 2012, 7, e29452. [CrossRef]
45. Servin, A.L. Antagonistic activities of lactobacilli and bifidobacteria against microbial pathogens. FEMS Microbiol. Rev. 2004, 28, 405–440. [CrossRef] [PubMed]
46. Ricke, S.C. Perspectives on the use of organic acids and short chain fatty acids as antimicrobials. Poult. Sci. 2003, 82, 632–639. [CrossRef] [PubMed]
47. Suiryanrayna, M.V.A.N.; Ramana, J.V. A review of the effects of dietary organic acids fed to swine. J. Anim. Sci. Biotechnol. 2015, 6. [CrossRef] [PubMed]
48. Slonczewski, J.L.; Fujisawa, M.; Dopson, M.; Krulwich, T.A. Cytoplasmic pH Measurement and Homeostasis in Bacteria and Archaea. In Advances in Microbial Physiology; Poole, R.K., Ed.; Academic Press: Cambridge, MA, USA, 2009; Volume 55, pp. 1–317.
49. Patel, R.M.; Denning, P.W. Therapeutic Use of Prebiotics, Probiotics, and Postbiotics to Prevent Necrotizing Enterocolitis: What is the Current Evidence? Clin. Perinatol. 2013, 40, 11–25. [CrossRef]
50. Kareem, K.Y.; Hooi Ling, F.; Teck Chwen, L.; May Foong, O.; Anjas Asmara, S. Inhibitory activity of postbiotic produced by strains of Lactobacillus plantarum using reconstituted media supplemented with inulin. Gut Pathog. 2014, 6, 23. [CrossRef]
51. Sharma, V.; Harjai, K.; Shukla, G. Effect of bacteriocin and exopolysaccharides isolated from probiotic on P. aeruginosa PAO1 biofilm. Folia Microbiol. (Praha) 2018, 63, 181–190. [CrossRef]
52. Li, P.; Gu, Q. Antimicrobial Effects of Probiotics and Novel Probiotic-Based Approaches for Infectious Diseases. Probiotics Curr. Knowl. Future Prospects 2018. [CrossRef]
53. Pridmore, R.D.; Pittet, A.-C.; Praplan, F.; Cavadini, C. Hydrogen peroxide production by Lactobacillus johnsonii NCC 533 and its role in anti-Salmonella activity. FEMS Microbiol. Lett. 2008, 283, 210–215. [CrossRef]
54. Wang, Y.; Gänzle, M.G.; Schwab, C. Exopolysaccharide Synthesized by Lactobacillus reuteri Decreases the Ability of Enterotoxigenic Escherichia coli To Bind to Porcine Erythrocytes. Appl Environ. Microbiol. 2010, 76, 4863–4866. [CrossRef]
55. Fanning, S.; Hall, L.J.; Cronin, M.; Zomer, A.; MacSharry, J.; Goulding, D.; O’Connell Motherway, M.; Shanahan, F.; Nally, K.; Dougan, G.; et al. Bifidobacterial surface-exopolysaccharide facilitates commensal-host interaction through immune modulation and pathogen protection. Proc. Natl. Acad. Sci. USA 2012, 109, 2108–2113. [CrossRef]
56. Abdelhamid, A.G.; Esaam, A.; Hazaa, M.M. Cell free preparations of probiotics exerted antibacterial and antibiofilm activities against multidrug resistant E. coli. Saudi Pharm. J. SPJ 2018, 26, 603–607. [CrossRef]
57. ′-Sialyllactose Modulate Virulence Gene Expression in Escherichia coli O157:H7 and Salmonella Typhimurium. Front. Microbiol. 2016, 7. [CrossRef] [PubMed]
58. Bayoumi, M.A.; Griffiths, M.W. In vitro inhibition of expression of virulence genes responsible for colonization and systemic spread of enteric pathogens using Bifidobacterium bifidum secreted molecules. Int. J. Food Microbiol. 2012, 156, 255–263. [CrossRef] [PubMed]
59. Chauvière, G.; Coconnier, M.H.; Kerneis, S.; Darfeuille-Michaud, A.; Joly, B.; Servin, A.L. Competitive exclusion of diarrheagenic Escherichia coli (ETEC) from human enterocyte-like Caco-2 cells by heat-killed Lactobacillus. FEMS Microbiol. Lett. 1992, 70, 213–217. [CrossRef]
60. Coconnier, M.H.; Bernet, M.F.; Chauvière, G.; Servin, A.L. Adhering heat-killed human Lactobacillus acidophilus, strain LB, inhibits the process of pathogenicity of diarrhoeagenic bacteria in cultured human intestinal cells. J. Diarrhoeal Dis. Res. 1993, 11, 235–242. [PubMed]
61. Muñoz-Quezada, S.; Bermudez-Brito, M.; Chenoll, E.; Genovés, S.; Gomez-Llorente, C.; Plaza-Diaz, J.; Matencio, E.; Bernal, M.J.; Romero, F.; Ramón, D.; et al. Competitive inhibition of three novel bacteria isolated from faeces of breast milk-fed infants against selected enteropathogens. Br. J. Nutr. 2013, 109, S63–S69. [CrossRef] [PubMed]
62. Tsai, C.-C.; Lin, P.-P.; Hsieh, Y.-M. Three Lactobacillus strains from healthy infant stool inhibit enterotoxigenic Escherichia coli grown in vitro. Anaerobe 2008, 14, 61–67. [CrossRef]
63. He, X.; Zeng, Q.; Puthiyakunnon, S.; Zeng, Z.; Yang, W.; Qiu, J.; Du, L.; Boddu, S.; Wu, T.; Cai, D.; et al. Lactobacillus rhamnosus GG supernatant enhance neonatal resistance to systemic Escherichia coli K1 infection by accelerating development of intestinal defense. Sci. Rep. 2017, 7, 43305. [CrossRef]
64. Gao, J.; Li, Y.; Wan, Y.; Hu, T.; Liu, L.; Yang, S.; Gong, Z.; Zeng, Q.; Wei, Y.; Yang, W.; et al. A Novel Postbiotic From Lactobacillus rhamnosus GG With a Beneficial Effect on Intestinal Barrier Function. Front. Microbiol. 2019, 10. [CrossRef]
65. Charchoghlyan, H.; Kwon, H.; Hwang, D.-J.; Lee, J.S.; Lee, J.; Kim, M. Inhibition of Cronobacter sakazakii by Lactobacillus acidophilus n.v. Er2 317/402. Korean J. Food Sci. Anim. Resour. 2016, 36, 635–640. [CrossRef]
66. Jamwal, A.; Sharma, K.; Chauhan, R.; Bansal, S.; Goel, G. Evaluation of commercial probiotic lactic cultures against biofilm formation by Cronobacter sakazakii. Intest. Res. 2018. [CrossRef] [PubMed]
67. Dowdell, P.; Chankhamhaengdecha, S.; Panbangred, W.; Janvilisri, T.; Aroonnual, A. Probiotic Activity of Enterococcus faecium and Lactococcus lactis Isolated from Thai Fermented Sausages and Their Protective Effect Against Clostridium difficile. Probiotics Antimicrob. Proteins 2019. [CrossRef] [PubMed]
68. Ephraim, E.; Schultz, R.D.; Safdar, N. Lactobacillus rhamnosus GG Protects Cells from Clostridium difficile Toxins. Br. Microbiol. Res. J. 2013, 3, 165–175. [CrossRef]
69. Tsilingiri, K.; Barbosa, T.; Penna, G.; Caprioli, F.; Sonzogni, A.; Viale, G.; Rescigno, M. Probiotic and postbiotic activity in health and disease: Comparison on a novel polarised ex-vivo organ culture model. Gut 2012, 61, 1007–1015. [CrossRef]
70. Bermudez-Brito, M.; Munoz-Quezada, S.; Gomez-Llorente, C.; Matencio, E.; Romero, F.; Gil, A. Lactobacillus paracasei CNCM I-4034 and its culture supernatant modulate Salmonella-induced inflammation in a novel transwell co-culture of human intestinal-like dendritic and Caco-2 cells. Bmc Microbiol. 2015, 15, 79. [CrossRef]
71. Rather, I.A.; Choi, K.-H.; Bajpai, V.K.; Park, Y.-H. Antiviral mode of action of Lactobacillus plantarum YML009 on Influenza virus H1N1. Bangladesh J. Pharmacol. 2015, 10, 475. [CrossRef]
72. Seo, B.J.; Rather, I.A.; Kumar, V.J.R.; Choi, U.H.; Moon, M.R.; Lim, J.H.; Park, Y.H. Evaluation of Leuconostoc mesenteroides YML003 as a probiotic against low-pathogenic avian influenza (H9N2) virus in chickens. J. Appl. Microbiol. 2012, 113, 163–171. [CrossRef]
73. Kaila, M.; Isolauri, E.; Saxelin, M.; Arvilommi, H.; Vesikari, T. Viable versus inactivated lactobacillus strain GG in acute rotavirus diarrhoea. Arch. Dis. Child. 1995, 72, 51–53. [CrossRef]
74. Martín, V.; Maldonado, A.; Fernández, L.; Rodríguez, J.M.; Connor, R.I. Inhibition of Human Immunodeficiency Virus Type 1 by Lactic Acid Bacteria from Human Breastmilk. Breastfeed. Med. 2010, 5, 153–158. [CrossRef]
75. Hassan, Z. Anti-Adhesion Activity of Lactic Acid Bacteria Supernatant against Human Pathogenic Candida Species Biofilm. Health Sci. J. 2015, 9.
76. Parolin, C.; Marangoni, A.; Laghi, L.; Foschi, C.; Palomino, R.A.Ñ.; Calonghi, N.; Cevenini, R.; Vitali, B. Isolation of Vaginal Lactobacilli and Characterization of Anti-Candida Activity. PLoS ONE 2015, 10, e0131220. [CrossRef] [PubMed]
77. Song, Y.-G.; Lee, S.-H. Inhibitory effects of Lactobacillus rhamnosus and Lactobacillus casei on Candida biofilm of denture surface. Arch. Oral Biol. 2017, 76, 1–6. [CrossRef] [PubMed]
78. Nocerino, R.; Paparo, L.; Terrin, G.; Pezzella, V.; Amoroso, A.; Cosenza, L.; Cecere, G.; Marco, G.D.; Micillo, M.; Albano, F.; et al. Cow’s milk and rice fermented with Lactobacillus paracasei CBA L74 prevent infectious diseases in children: A randomized controlled trial. Clin. Nutr. 2017, 36, 118–125. [CrossRef] [PubMed]
79. Thibault, H.; Aubert-Jacquin, C.; Goulet, O. Effects of Long-term Consumption of a Fermented Infant Formula (with Bifidobacterium breve c50 and Streptococcus thermophilus 065) on Acute Diarrhea in Healthy Infants. J. Pediatr. Gastroenterol. Nutr. 2004, 39, 147. [CrossRef] [PubMed]
80. Romond, M.B.; Ais, A.; Yazourh, A.; Romond, C. Cell-free Wheys From Bifidobacteria Fermented Milks Exert a Regulatory Effect on the Intestinal Microflora of Mice and Humans. Anaerobe 1997, 3, 137–143. [CrossRef]
81. Arai, S.; Iwabuchi, N.; Takahashi, S.; Xiao, J.; Abe, F.; Hachimura, S. Orally administered heat-killed Lactobacillus paracasei MCC1849 enhances antigen-specific IgA secretion and induces follicular helper T cells in mice. PLoS ONE 2018, 13, e0199018. [CrossRef]
82. Good, M.; Sodhi, C.P.; Ozolek, J.A.; Buck, R.H.; Goehring, K.C.; Thomas, D.L.; Vikram, A.; Bibby, K.; Morowitz, M.J.; Firek, B.; et al. Lactobacillus rhamnosus HN001 decreases the severity of necrotizing enterocolitis in neonatal mice and preterm piglets: Evidence in mice for a role of TLR9. Am. J. Physiol. Gastrointest. Liver Physiol. 2014, 306, G1021–G1032. [CrossRef]
83. Zheng, J.; Wittouck, S.; Salvetti, E.; Franz, C.M.A.P.; Harris, H.M.B.; Mattarelli, P.; O’Toole, P.W.; Pot, B.; Vandamme, P.; Walter, J.; et al. A taxonomic note on the genus Lactobacillus: Description of 23 novel genera, emended description of the genus Lactobacillus Beijerinck 1901, and union of Lactobacillaceae and Leuconostocaceae. Int. J. Syst. Evol. Microbiol. 2020, 70, 2782–2858. [CrossRef]
84. Kotloff, K.L.; Nataro, J.P.; Blackwelder, W.C.; Nasrin, D.; Farag, T.H.; Panchalingam, S.; Wu, Y.; Sow, S.O.; Sur, D.; Breiman, R.F.; et al. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): A prospective, case-control study. Lancet 2013, 382, 209–222. [CrossRef]
85. Kotloff, K.L.; Nasrin, D.; Blackwelder, W.C.; Wu, Y.; Farag, T.; Panchalingham, S.; Sow, S.O.; Sur, D.; Zaidi, A.K.M.; Faruque, A.S.G.; et al. The incidence, aetiology, and adverse clinical consequences of less severe diarrhoeal episodes among infants and children residing in low-income and middle-income countries: A 12-month case-control study as a follow-on to the Global Enteric Multicenter Study (GEMS). Lancet Glob. Health 2019, 7, e568–e584. [CrossRef]
86. Liévin-Le Moal, V. A gastrointestinal anti-infectious biotherapeutic agent: The heat-treated Lactobacillus LB. Ther. Adv. Gastroenterol. 2016, 9, 57–75. [CrossRef] [PubMed]
87. Chauvière, G.; Coconnier, M.H.; Kernéis, S.; Fourniat, J.; Servin, A.L. Adhesion of human Lactobacillus acidophilus strain LB to human enterocyte-like Caco-2 cells. J. Gen. Microbiol. 1992, 138, 1689–1696. [CrossRef] [PubMed]
88. Muñoz-Quezada, S.; Chenoll, E.; Vieites, J.M.; Genovés, S.; Maldonado, J.; Bermúdez-Brito, M.; Gomez-Llorente, C.; Matencio, E.; Bernal, M.J.; Romero, F.; et al. Isolation, identification and characterisation of three novel probiotic strains (Lactobacillus paracasei CNCM I-4034, Bifidobacterium breve CNCM I-4035 and Lactobacillus rhamnosus CNCM I-4036) from the faeces of exclusively breast-fed infants. Br. J. Nutr. 2013, 109 (Suppl. 2), S51–S62. [CrossRef]
89. Zhang, H.; Gao, J.; He, X.; Gong, Z.; Wan, Y.; Hu, T.; Li, Y.; Cao, H. The postbiotic HM0539 from Lactobacillus rhamnosus GG prevents intestinal infection by enterohemorrhagic E. coli O157: H7 in mice. J. South. Med. Univ. 2020, 40, 211–218. [CrossRef]
90. Agostoni, C.; Axelsson, I.; Goulet, O.; Koletzko, B.; Michaelsen, K.F.; Puntis, J.W.L.; Rigo, J.; Shamir, R.; Szajewska, H.; Turck, D.; et al. Preparation and Handling of Powdered Infant Formula: A Commentary by the ESPGHAN Committee on Nutrition. J. Pediatr. Gastroenterol. Nutr. 2004, 39, 320–322. [CrossRef]
91. Borali, E.; De Giacomo, C. Clostridium Difficile Infection in Children: A Review. J. Pediatr. Gastroenterol. Nutr. 2016, 63, e130–e140. [CrossRef]
92. Plants-Paris, K.; Bishoff, D.; Oyaro, M.O.; Mwinyi, B.; Chappell, C.; Kituyi, A.; Nyangao, J.; Mbatha, D.; Darkoh, C. Prevalence of Clostridium difficile infections among Kenyan children with diarrhea. Int. J. Infect. Dis. 2019, 81, 66–72. [CrossRef]
93. Jangi, S.; Lamont, J. Asymptomatic Colonization by Clostridium difficile in Infants: Implications for Disease in Later Life. J. Pediatr. Gastroenterol. Nutr. 2010, 51, 2–7. [CrossRef]
94. Schäffler, H.; Breitrück, A. Clostridium difficile–From Colonization to Infection. Front. Microbiol. 2018, 9, 646. [CrossRef]
95. Fiedoruk, K.; Daniluk, T.; Rozkiewicz, D.; Zaremba, M.L.; Oldak, E.; Sciepuk, M.; Leszczynska, K. Conventional and molecular methods in the diagnosis of community-acquired diarrhoea in children under 5 years of age from the north-eastern region of Poland. Int. J. Infect. Dis. 2015, 37, 145–151. [CrossRef]
96. Dunand, E.; Burns, P.; Binetti, A.; Bergamini, C.; Peralta, G.H.; Forzani, L.; Reinheimer, J.; Vinderola, G. Postbiotics produced at laboratory and industrial level as potential functional food ingredients with the capacity to protect mice against Salmonella infection. J. Appl. Microbiol. 2019, 127, 219–229. [CrossRef] [PubMed]
97. Lafond, K.E.; Nair, H.; Rasooly, M.H.; Valente, F.; Booy, R.; Rahman, M.; Kitsutani, P.; Yu, H.; Guzman, G.; Coulibaly, D.; et al. Global Role and Burden of Influenza in Pediatric Respiratory Hospitalizations, 1982–2012: A Systematic Analysis. PLoS Med. 2016, 13. [CrossRef] [PubMed]
98. El Guerche-Séblain, C.; Moureau, A.; Schiffler, C.; Dupuy, M.; Pepin, S.; Samson, S.I.; Vanhems, P.; Schellevis, F. Epidemiology and burden of influenza in healthy children aged 6 to 35 months: Analysis of data from the placebo arm of a phase III efficacy trial. BMC Infect. Dis. 2019, 19, 308. [CrossRef] [PubMed]
99. de Francisco (Shapovalova), N.; Donadel, M.; Jit, M.; Hutubessy, R. A systematic review of the social and economic burden of influenza in low-and middle-income countries. Vaccine 2015, 33, 6537–6544. [CrossRef]
100. Thorrington, D.; Balasegaram, S.; Cleary, P.; Hay, C.; Eames, K. Social and Economic Impacts of School Influenza Outbreaks in England: Survey of Caregivers. J. Sch. Health 2017, 87, 209–216. [CrossRef]
101. Hagbom, M.; Sharma, S.; Lundgren, O.; Svensson, L. Towards a human rotavirus disease model. Curr. Opin. Virol. 2012, 2, 408–418. [CrossRef]
102. Simakachorn, N.; Pichaipat, V.; Rithipornpaisarn, P.; Kongkaew, C.; Tongpradit, P.; Varavithya, W. Clinical evaluation of the addition of lyophilized, heat-killed Lactobacillus acidophilus LB to oral rehydration therapy in the treatment of acute diarrhea in children. J. Pediatr. Gastroenterol. Nutr. 2000, 30, 68–72. [CrossRef]
103. Salazar-Lindo, E.; Figueroa-Quintanilla, D.; Caciano, M.; Reto-Valiente, V.; Chauviere, G.; Colin, P. Effectiveness and Safety of Lactobacillus LB in the Treatment of Mild Acute Diarrhea in Children. J. Pediatr. Gastroenterol. Nutr. 2007, 44, 571–576. [CrossRef]
104. Osano, B.O.; Were, F.; Mathews, S. Mortality among 5-17 year old children in Kenya. Pan Afr. Med. J. 2017, 27. [CrossRef]
105. Buvé, A.; Bishikwabo-Nsarhaza, K.; Mutangadura, G. The spread and effect of HIV-1 infection in sub-Saharan Africa. Lancet 2002, 359, 2011–2017. [CrossRef]
106. WHO Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants. Available online: https://apps.who.int/iris/bitstream/handle/10665/75236/9789241599818_eng.pdf?sequence= 1 (accessed on 17 August 2020).
107. WHO Guidelines on HIV and Infant Feeding. 2010. Available online: http://www.who.int/maternal_child_ adolescent/documents/9789241599535/en/(accessed on 17 August 2020).
108. WHO HIV and Infant Feeding: Update. Available online: https://apps.who.int/iris/bitstream/handle/10665/43747/9789241595964_eng.pdf;jsessionid=3D425244271D458E9F10E85E311DFBCD?sequence=1 (accessed on 17 August 2020).
109. White, A.B.; Mirjahangir, J.F.; Horvath, H.; Anglemyer, A.; Read, J.S. Antiretroviral interventions for preventing breast milk transmission of HIV. Cochrane Database Syst. Rev. 2014. [CrossRef] [PubMed]
110. Toda, M. Population-Based Active Surveillance for Culture-Confirmed Candidemia — Four Sites, United States, 2012–2016. MMWR Surveill. Summ. 2019, 68. [CrossRef] [PubMed]
111. Noni, M.; Stathi, A.; Vaki, I.; Velegraki, A.; Zachariadou, L.; Michos, A. Changing Epidemiology of Invasive Candidiasis in Children during a 10-Year Period. J. Fungi 2019, 5, 19. [CrossRef] [PubMed]
112. Kaufman, D.; Boyle, R.; Hazen, K.C.; Patrie, J.T.; Robinson, M.; Donowitz, L.G. Fluconazole prophylaxis against fungal colonization and infection in preterm infants. N. Engl. J. Med. 2001, 345, 1660–1666. [CrossRef]
113. Gephart, S.M.; McGrath, J.M.; Effken, J.A.; Halpern, M.D. Necrotizing Enterocolitis Risk: State of the Science. Adv. Neonatal Care 2012, 12, 77–87. [CrossRef]
114. Coggins, S.A.; Wynn, J.L.; Weitkamp, J.-H. Infectious causes of necrotizing enterocolitis. Clin. Perinatol. 2015, 42, 133. [CrossRef]
115. Wu, W.; Wang, Y.; Zou, J.; Long, F.; Yan, H.; Zeng, L.; Chen, Y. Bifidobacterium adolescentis protects against necrotizing enterocolitis and upregulates TOLLIP and SIGIRR in premature neonatal rats. BMC Pediatr. 2017, 17, 1. [CrossRef]
116. Schönherr-Hellec, S.; Klein, G.L.; Delannoy, J.; Ferraris, L.; Rozé, J.C.; Butel, M.J.; Aires, J. Clostridial Strain-Specific Characteristics Associated with Necrotizing Enterocolitis. Appl Environ. Microbiol 2018, 84, e02428-17. [CrossRef]
117. Alfa, M.J.; Robson, D.; Davi, M.; Bernard, K.; Caeseele, P.V.; Harding, G.K.M. An Outbreak of Necrotizing Enterocolitis Associated with a Novel Clostridium Species in a Neonatal Intensive Care Unit. Clin. Infect. Dis. 2002, 35, S101–S105. [CrossRef]
118. Denning, N.-L.; Prince, J.M. Neonatal intestinal dysbiosis in necrotizing enterocolitis. Mol. Med. 2018, 24, 4. [CrossRef]
119. Land, M.H.; Rouster-Stevens, K.; Woods, C.R.; Cannon, M.L.; Cnota, J.; Shetty, A.K. Lactobacillus Sepsis Associated With Probiotic Therapy. Pediatrics 2005, 115, 178–181. [CrossRef] [PubMed]
120. Patel, R.M.; Underwood, M.A. Probiotics and Necrotizing Enterocolitis. Semin. Pediatr. Surg. 2018, 27, 39–46. [CrossRef] [PubMed]
121. Chiang, M.-C.; Chen, C.-L.; Feng, Y.; Chen, C.-C.; Lien, R.; Chiu, C.-H. Lactobacillus rhamnosus sepsis associated with probiotic therapy in an extremely preterm infant: Pathogenesis and a review for clinicians. J. Microbiol. Immunol. Infect. 2020. [CrossRef] [PubMed]
122. Su, G.L.; Ko, C.W.; Bercik, P.; Falck-Ytter, Y.; Sultan, S.; Weizman, A.V.; Morgan, R.L. AGA Clinical Practice Guidelines on the Role of Probiotics in the Management of Gastrointestinal Disorders. Gastroenterology 2020. [CrossRef]
123. van den Akker, C.H.P.; van Goudoever, J.B.; Shamir, R.; Domellöf, M.; Embleton, N.D.; Hojsak, I.; Lapillonne, A.; Mihatsch, W.A.; Berni Canani, R.; Bronsky, J.; et al. Probiotics and Preterm Infants: A Position Paper by the European Society for Paediatric Gastroenterology Hepatology and Nutrition Committee on Nutrition and the European Society for Paediatric Gastroenterology Hepatology and Nutrition Working Group for Probiotics and Prebiotics. J. Pediatr. Gastroenterol. Nutr. 2020, 70, 664–680. [CrossRef] [PubMed]
124. Vieira, A.T.; Fukumori, C.; Ferreira, C.M. New insights into therapeutic strategies for gut microbiota modulation in inflammatory diseases. Clin. Transl. Immunol. 2016, 5, e87. [CrossRef] [PubMed]
125. Mosca, F.; Gianni, M.L.; Rescigno, M. Can Postbiotics Represent a New Strategy for NEC? Adv. Exp. Med. Biol. 2019. [CrossRef]
126. Campeotto, F.; Suau, A.; Kapel, N.; Magne, F.; Viallon, V.; Ferraris, L.; Waligora-Dupriet, A.-J.; Soulaines, P.; Leroux, B.; Kalach, N.; et al. A fermented formula in pre-term infants: Clinical tolerance, gut microbiota, down-regulation of faecal calprotectin and up-regulation of faecal secretory IgA. Br. J. Nutr. 2011, 105, 1843–1851. [CrossRef]
127. Ehrenkranz, R.A.; Dusick, A.M.; Vohr, B.R.; Wright, L.L.; Wrage, L.A.; Poole, W.K. Growth in the Neonatal Intensive Care Unit Influences Neurodevelopmental and Growth Outcomes of Extremely Low Birth Weight Infants. Pediatrics 2006, 117, 1253–1261. [CrossRef]
128. Jeong, S.J. The role of fecal calprotectin in pediatric disease. Korean J. Pediatr. 2019, 62, 287–291. [CrossRef]
129. Mullié, C.; Yazourh, A.; Thibault, H.; Odou, M.-F.; Singer, E.; Kalach, N.; Kremp, O.; Romond, M.-B. Increased Poliovirus-Specific Intestinal Antibody Response Coincides with Promotion of Bifidobacterium longum-infantis and Bifidobacterium breve in Infants: A Randomized, Double-Blind, Placebo-Controlled Trial. Pediatr. Res. 2004, 56, 791–795. [CrossRef] [PubMed]
130. Morrison, D.J.; Preston, T. Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. Gut Microbes 2016, 7, 189–200. [CrossRef] [PubMed]
131. Barczyńska, R.; Litwin, M.; Sliżewska, K.; Szalecki, M.; Berdowska, A.; Bandurska, K.; Libudzisz, Z.; Kapuśniak, J. Bacterial Microbiota and Fatty Acids in the Faeces of Overweight and Obese Children. Pol. J. Microbiol. 2018, 67, 339–345. [CrossRef] [PubMed]
132. Riva, A.; Borgo, F.; Lassandro, C.; Verduci, E.; Morace, G.; Borghi, E.; Berry, D. Pediatric obesity is associated with an altered gut microbiota and discordant shifts in F irmicutes populations. Environ. Microbiol. 2017, 19, 95–105. [CrossRef]
133. Ibrahim, M.K.; Zambruni, M.; Melby, C.L.; Melby, P.C. Impact of Childhood Malnutrition on Host Defense and Infection. Clin. Microbiol. Rev. 2017, 30, 919–971. [CrossRef]
134. Rocha-Ramírez, L.M.; Hernández-Ochoa, B.; Gómez-Manzo, S.; Marcial-Quino, J.; Cárdenas-Rodríguez, N.; Centeno-Leija, S.; García-Garibay, M. Impact of Heat-Killed Lactobacillus casei Strain IMAU60214 on the Immune Function of Macrophages in Malnourished Children. Nutrients 2020, 12, 2303. [CrossRef]
135. van der Lelie, D.; Taghavi, S. COVID-19 and the Gut Microbiome: More than a Gut Feeling. mSystems 2020, 5, e00453-20. [CrossRef]
136. Gou, W.; Fu, Y.; Yue, L.; Chen, G.; Cai, X.; Shuai, M.; Xu, F.; Yi, X.; Chen, H.; Zhu, Y.J.; et al. Gut microbiota may underlie the predisposition of healthy individuals to COVID-19. medRxiv 2020. [CrossRef]
137. Kalantar-Zadeh, K.; Ward, S.A.; Kalantar-Zadeh, K.; El-Omar, E.M. Considering the Effects of Microbiome and Diet on SARS-CoV-2 Infection: Nanotechnology Roles. ACS Nano 2020, 14, 5179–5182. [CrossRef]